Monday, December 23, 2024
Advertisement
  1. You Are At:
  2. News
  3. India
  4. Does India have the doses to fulfil Phase-1 Covid vaccine goals?

Does India have the doses to fulfil Phase-1 Covid vaccine goals?

Given that India has set the goal of vaccinating 30 crore people with Covid-19 jabs by July, can the country procure enough doses to fulfil that goal?

Edited by: IANS New Delhi Published : Jan 02, 2021 17:37 IST, Updated : Jan 02, 2021 17:38 IST
Coronavirus vaccine, vaccine, covid19 vaccine, pandemic
Image Source : AP

A health worker gets a shot of the vaccine. (Representational image)

Given that India has set the goal of vaccinating 30 crore people with Covid-19 jabs by July, can the country procure enough doses to fulfill that goal? To vaccinate 30 crore people, the country will need 60 crore doses as the two vaccines that are leading the race to get approval from the government require two-doses per person for protection.

These two vaccines that the government is currently considering giving the approval are "Covishield" and "Covaxin".

While the Pune-based Serum Institute of India has partnered with Oxford-AstraZeneca for conducting clinical trials and manufacturing "Covishield", Bharat Biotech has collaborated with the Indian Council of Medical Research (ICMR) for "Covaxin".

ALSO READCovid vaccination: Dry run across India, who will get it first, how to register | Everything you need to know

 

Approval for Covishield is expected soon as the Subject Expert Committee of the Central Drug Standard Control Organisation on Friday recommended its emergency use.

Serum Institute to provide 30 crore vaccine doses to govt by July

However, it now appears that the Serum Institute of India is planning to supply the government with 30 crore doses by July, enough for vaccinating 15 crore people, according to media reports. If it works out that way, the government will be able to reach just half-way of fulfilling the phase-1 goals with Covishield alone.

"For rolling out the vaccination campaign, cold chain equipment such as walk-in coolers, walk-in freezers, refrigerators, deep freezers are already procured and distributed to the states," Harshal R Salve, Associate Professor at Centre for Community Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi.

"Vaccine storage capacities at airports and major railway staions are being created."

Approval for second vaccine on the way?

"You may have approval for another vaccine too in the meanwhile that can be included in the mass the vaccination drive," Salve added. It now appears that the success of India's vaccination drive may rely on the efficacy of Covaxin in protecting people against Covid-19.

This is specially in view of the fact that India did not sign early procurement deals for the other two vaccines that have got approval in several countries including the US -- the vaccines developed by Pfizer-BioNTech and Moderna.

What about Pfizer, Moderna use in India?

As these two vaccines are now in great demand, they appear unprepared to supply India huge number of doses quickly even if New Delhi fast-tracks their approvals. Pfizer has already sought the emergency use authorisation for its Covid-19 vaccine in India. Now experts believe that to achieve herd immunity against Covid-19, about 70 per cent of the country's population will have to be vaccinated, meaning about 90 crore people. If other vaccines that are approved in the future also require two doses per person, this will mean that India will need 180 crore doses of Covid-19 vaccines.

Union Health Minister Harsh Vardhan earlier this month said that about 30 vaccines against Covid-19 are in different stages of development in India. How many of them get the required approval may say a lot about how quickly India achieves herd immunity against Covid-19.

ALSO READCoWin Coronavirus Vaccine tracking app available for Android, iPhone: How to download, use

 

Advertisement

Read all the Breaking News Live on indiatvnews.com and Get Latest English News & Updates from India

Advertisement
Advertisement
Advertisement
Advertisement